Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Vicente Escudero-VilaplanaRoberto Collado-BorrellMaria Del Monte-MillánAngela Hoyo-MuñozPatricia Gómez Martínez-SagreraJose Luis Revuelta-HerreroBelen Marzal-AlfaroEva Gonzalez-HabaSara López-Tarruella CoboYolanda Jerez GilarranzAna HerranzMaria SanjurjoMiguel MartinPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)
More than a third of patients in treatment with OAAs presented diarrhea (any grade), and 22.1% of stools were semi-liquid/liquid. In multivariate analysis, taking the OAA on an empty stomach was associated with a statistically significant increase in the incidence of diarrhea.